Mazdutide vs retatrutide

Mazdutide acts on the GLP-1 and glucagon receptors and was approved in China in 2025 for weight management and type 2 diabetes. Retatrutide also acts on the GIP receptor and is in phase 3 trials, and neither is approved in the US or EU. This page compares their study results.

Best randomized result by outcome

For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.

Best randomized result by outcome for Mazdutide, Retatrutide
Outcome	Mazdutide	Retatrutide
Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in %	−10.09% Body weight change · mazdutide 4 mg, week 32 Dose studied: 4 mg once weekly32 weeksn = 6102025	−23.7% Percent change in body weight · retatrutide 9 mg Placebo: −3.9% Dose studied: 9 mg80 weeksn not reported2026
Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in %	−1.41% HbA1c change, smallest Dose studied: 3 mg, 4.5 mg or 6 mg20 weeksn not reported2024	−1.69% HbA1c change · retatrutide 4 mg Dose studied: 4 mg once weekly40 weeksn not reported2026
Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in %	1.5% Discontinuation due to AE · mazdutide 4 mg Placebo: 1% Dose studied: 4 mg once weekly48 weeksn = 6102025	4% Permanent discontinuation · retatrutide 4 mg Placebo: 5% Dose studied: 4 mgn = 5812026
Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in %	29.2% Incidence · IBI362 Placebo: 0% Dose studied: 3.0 mg, 4.5 mg or 6.0 mg12 weeksn not reported2022	27% Participants with diarrhoea · retatrutide 4 mg Placebo: 13% Dose studied: 4 mgn = 5792026

Body weightMetabolic and weightCompared as: value in the arm that got the peptide, in %
- Mazdutide
  −10.09%
  Body weight change · mazdutide 4 mg, week 32
  Dose studied: 4 mg once weekly32 weeksn = 6102025
- Retatrutide
  −23.7%
  Percent change in body weight · retatrutide 9 mg
  Placebo: −3.9%
  Dose studied: 9 mg80 weeksn not reported2026
Glycemic controlMetabolic and weightCompared as: value in the arm that got the peptide, in %
- Mazdutide
  −1.41%
  HbA1c change, smallest
  Dose studied: 3 mg, 4.5 mg or 6 mg20 weeksn not reported2024
- Retatrutide
  −1.69%
  HbA1c change · retatrutide 4 mg
  Dose studied: 4 mg once weekly40 weeksn not reported2026
Adverse eventsWhole bodyCompared as: value in the arm that got the peptide, in %
- Mazdutide
  1.5%
  Discontinuation due to AE · mazdutide 4 mg
  Placebo: 1%
  Dose studied: 4 mg once weekly48 weeksn = 6102025
- Retatrutide
  4%
  Permanent discontinuation · retatrutide 4 mg
  Placebo: 5%
  Dose studied: 4 mgn = 5812026
Gastrointestinal adverse eventsGastrointestinalCompared as: share of people in the arm that got the peptide, in %
- Mazdutide
  29.2%
  Incidence · IBI362
  Placebo: 0%
  Dose studied: 3.0 mg, 4.5 mg or 6.0 mg12 weeksn not reported2022
- Retatrutide
  27%
  Participants with diarrhoea · retatrutide 4 mg
  Placebo: 13%
  Dose studied: 4 mgn = 5792026

Comparing 2 peptides · Data version 308560

Only differences

Swipe sideways to see every peptide.

Comparison of Mazdutide, Retatrutide
Peptide	Synthetic analog Mazdutide	Synthetic analog Retatrutide
Identity
Kind	Synthetic analog	Synthetic analog
Area	Weight and metabolic	Weight and metabolic
Evidence
Amount of evidence	186	380
Evidence level	Has results from studies in people	Has results from studies in people
Safety
Safety results	62 (62 in people)	61 (61 in people)
Status
Approval
Sport (WADA)
Registered trials	45 · 25 active	34 · 11 active

Shared outcomes

Body weight161
Adverse events69
Glycemic control52
Gastrointestinal adverse events47
Lipids36
Liver fat and liver function29
Appetite and food intake21
Receptor activity and mechanism32
Inflammation markers18
Blood pressure7
Metabolic pathways and metabolomics3
Neuroprotection5

Approval and sport status

From the regulatory data of each peptide.

Mazdutide
No FDA approval and no central EU authorisation (EMA).
Retatrutide
Its most advanced trial is in phase 3. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).

Amount of evidence by outcome

Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.

Study results per shared outcome group and evidence class
Outcome group	Mazdutide	Retatrutide
Body weightMetabolic and weight	6363	987919
Adverse eventsWhole body	3131	3838
Glycemic controlMetabolic and weight	2020	32266
Gastrointestinal adverse eventsGastrointestinal	3030	1717
LipidsMetabolic and weight	9711	271611
Liver fat and liver functionLiver	9162	20137
Appetite and food intakeMetabolic and weight	22	19136
Receptor activity and mechanismLiver	844	24816
Inflammation markersLiver	422	14410
Blood pressureCardiovascular	33	44
Metabolic pathways and metabolomicsMetabolic and weight	11	22
NeuroprotectionNervous system and cognition	22	33

Sequence alignment

Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.

Against Oxyntomodulin (human)Mazdutide

Mazdutide differs from Oxyntomodulin (human) at 15 positions.

Top row: Oxyntomodulin (human) (parent)
Bottom row: Mazdutide

HQGTFTSDY

SKYLDA

FVWL

Same as parent
Substituted
Non-canonical or D-form
Modified side chain or end
Parent context

What is different

1Position 2: Ser is replaced by Aib, an amino acid that is not one of the standard 20.
2Position 16: Ser is replaced by Glu.
3Position 17: Arg is replaced by Lys.
4Position 18: Arg is replaced by Lys.
5Position 20: Gln is replaced by Lys.
6Position 21: Asp is replaced by Glu.
7Position 24: Gln is replaced by Glu.
8Position 27: Met is replaced by Leu.
9Position 28: Asn is replaced by Glu.
10Position 29: Thr is replaced by Gly.
11Position 30: Lys is replaced by Gly.
12Position 31: Arg is replaced by Pro.
13Position 32: Asn is replaced by Ser.
14Position 33: Arg is replaced by Ser.
15Position 34: Asn is replaced by Gly.

Against Gastric inhibitory polypeptide (GIP)Retatrutide

Retatrutide differs from Gastric inhibitory polypeptide (GIP) at 15 positions and in 1 end segment.

Top row: Gastric inhibitory polypeptide (GIP) (parent)
Bottom row: Retatrutide

YGTFSDY

SIDKQ

FLL

PSSGAPPPS

Same as parent
Substituted
Non-canonical or D-form
Modified side chain or end
Replaced segment
Parent context

What is different

1Position 2: Ala is replaced by Aib, an amino acid that is not one of the standard 20.
2Position 3: Glu is replaced by Gln.
3Position 7: Ile is replaced by Thr.
4Position 13: Ala is replaced by alphaMeLeu, an amino acid that is not one of the standard 20.
5Position 14: Met is replaced by Leu.
6Position 17: Ile is replaced by Lys.
7Position 18: His is replaced by Ala.
8Position 20: Gln is replaced by Aib, an amino acid that is not one of the standard 20.
9Position 21: Asp is replaced by Ala.
10Position 23: Val is replaced by Ile.
11Position 24: Asn is replaced by Glu.
12Position 25: Trp is replaced by Tyr.
13Position 28: Ala is replaced by Glu.
14Position 29: Gln is replaced by Gly.
15Position 30: Lys is replaced by Gly.
16Positions 31 to 39: the end of the peptide is a different stretch of amino acids, not a set of single swaps.

Trials side by side

Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.

Mazdutide45 registered trials

Top 3 of 45 trials, ranked by phase, then posted results and enrollment: 2 not yet recruiting · 1 completed · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 3NCT07417306